logo

For the Inventor, By the Inventor

Bedminster, NJ, United States of America

Sukanthini Thurairatnam

This inventor holds 13 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Aventis Pharmaceuticals Inc., Axys Pharmaceuticals, Inc., Genzyme Corporation. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sukanthini Thurairatnam. Retrieved from https://idiyas.com/inventor/sukanthini-thurairatnam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 

% Patents Active = 53.8

 

Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 27(Granted Patents)


Location History:

  • Bedminster, NJ (US) (2005 - 2012)
  • Bridgewater, NJ (US) (2021)

Company Filing History:

goldMedal7 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents
silverMedal5 out of 40 
 
Axys Pharmaceuticals, Inc.
 patents
bronzeMedal4 out of 825 
 
Genzyme Corporation
 patents
4. 2 out of 2 
 
Sionna Therapeutics Inc.
 patents
5. 1 out of 377 
 
Aventis Pharma S.a.
 patents
6. 1 out of 1,547 
 
Sanofi
 patents
where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 12753171 - 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity (2026-10-06),
2. 12649750 - Macrocyclic compounds, compositions, and methods of using thereof (2026-06-09),
3. 12624051 - Macrocyclic compounds, compositions, and methods of using thereof (2026-05-12),
4. 11098056 - UDP glycosyltransferase inhibitors and methods of use (2021-08-24),
5. 8258130 - Pyrimidine hydrazide compounds as PGDS inhibitors (2012-09-04),
6. 8202863 - Pyrimidine amide compounds as PGDS inhibitors (2012-06-19),
7. 7482448 - Compounds and compositions as cathepsin inhibitors (2009-01-27),
8. 7226921 - Compounds and compositions as cathepsin S inhibitors (2007-06-05),
9. 7196099 - Compounds and compositions as cathepsin inhibitors (2007-03-27),
10. 7148215 - Chemical compounds (2006-12-12),
11. 7064123 - Compounds and compositions as cathepsin inhibitors (2006-06-20),
12. 7030116 - Compounds and compositions as cathepsin inhibitors (2006-04-18),
13. 6977256 - Compounds and compositions as cathepsin S inhibitors (2005-12-20),

Title: Sukanthini Thurairatnam: Innovator in Pharmaceutical Compounds

Introduction

Sukanthini Thurairatnam is a notable inventor based in Bedminster, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target allergic and inflammatory disorders. With a total of nine patents to his name, his work has the potential to impact many lives.

Latest Patents

Thurairatnam's latest patents include innovative compounds aimed at treating various health conditions. One of his notable inventions is the Pyrimidine hydrazide compounds as PGDS inhibitors. This invention focuses on a compound that can be used in pharmaceutical compositions to treat allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). Another significant patent is the Pyrimidine amide compounds as PGDS inhibitors, which shares a similar focus on treating allergic and inflammatory disorders.

Career Highlights

Throughout his career, Sukanthini Thurairatnam has worked with prominent companies in the pharmaceutical industry. He has been associated with Aventis Pharmaceuticals Inc. and Axys Pharmaceuticals, Inc., where he contributed to various research and development projects. His expertise in creating pharmaceutical compounds has established him as a valuable asset in the field.

Collaborations

Thurairatnam has collaborated with several professionals during his career. Notable coworkers include David John Aldous and Michael Gra

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…